Rubio-Guerra Alberto Francisco, Arceo-Navarro Adalberto, Vargas-Ayala German, Rodriguez-Lopez Leticia, Lozano-Nuevo Jose Juan, Gomez-Harper Carlos Treviño
Hypertension CLinic, Hospital General de Ticoman, Mexico City, Mexico.
Diabetes Care. 2004 Jul;27(7):1688-91. doi: 10.2337/diacare.27.7.1688.
To compare the effect of fixed-dose trandolapril-verapamil (FDTV) with that of trandolapril on proteinuria in normotensive, type 2 diabetic patients.
A total of 60 normotensive, type 2 diabetic patients with 24-h proteinuria >300 mg were randomly assigned to two groups for open-label treatment. One group received 2 mg trandolapril/180 mg verapamil FDTV once daily; the other group received 2 mg trandolapril once daily. Study drugs were administered for 6 months in both groups. Creatinine clearance and 24-h urinary protein excretion were measured at the beginning and the end of the study. Patients were evaluated monthly for blood pressure, fasting blood glucose level, heart rate, and adverse events. Statistical analysis was performed using ANOVA.
Both groups experienced a statistically significant (P < 0.005) mean decrease in mean proteinuria from baseline: FDTV ([mean +/- SD] 1200 +/- 200 to 540 +/- 79 mg; P < 0.001) and trandolapril (1,105 +/- 212 to 750.9 +/- 134 mg; P < 0.005). A significantly greater reduction from baseline in proteinuria was observed in the FDTV group compared with the trandolapril group. Patients who received trandolapril experienced a statistically significant (P < 0.05) decrease in mean creatinine clearance (91.1 +/- 3.4 to 75.3 +/- 3 ml/min; P < 0.05) compared with patients who received FDTV (88.3 +/- 3.6 to 82.9 +/- 3.5 ml/min; P > 0.05). Final fasting blood glucose was significantly lower in the FDTV group (139 +/- 19) compared with the trandolapril group (154 +/- 22; P < 0.001). No significant differences were observed between the two groups in mean baseline or final measurements of blood pressure, mean heart rate, or frequency of adverse events.
Our results suggest that FDTV is more effective than trandolapril in reducing proteinuria in normotensive, type 2 diabetic patients. This effect on proteinuria is not related with blood pressure reduction.
比较固定剂量的群多普利-维拉帕米(FDTV)与群多普利对血压正常的2型糖尿病患者蛋白尿的影响。
共有60例血压正常、24小时蛋白尿>300mg的2型糖尿病患者被随机分为两组进行开放标签治疗。一组每日服用一次2mg群多普利/180mg维拉帕米的FDTV;另一组每日服用2mg群多普利。两组均服用研究药物6个月。在研究开始和结束时测量肌酐清除率和24小时尿蛋白排泄量。每月评估患者的血压、空腹血糖水平、心率和不良事件。使用方差分析进行统计分析。
两组患者的蛋白尿均值从基线水平均有统计学显著下降(P<0.005):FDTV组([均值±标准差]1200±200降至540±79mg;P<0.001)和群多普利组(1105±212降至750.9±134mg;P<0.005)。与群多普利组相比,FDTV组蛋白尿从基线水平的下降幅度显著更大。与接受FDTV的患者(88.3±3.6降至82.9±3.5ml/min;P>0.05)相比,接受群多普利的患者平均肌酐清除率有统计学显著下降(91.1±3.4降至75.3±3ml/min;P<0.05)。FDTV组的最终空腹血糖(139±19)显著低于群多普利组(154±22;P<0.001)。两组在平均基线血压或最终血压测量值、平均心率或不良事件发生率方面未观察到显著差异。
我们的结果表明,在降低血压正常的2型糖尿病患者蛋白尿方面,FDTV比群多普利更有效。这种对蛋白尿的作用与血压降低无关。